Skip to content
  • Clinical Evidence
  • PAD
    • PAD
    • DETOUR System
    • DETOUR System Evidence
    • DETOUR System Resources
    • DETOUR System Reimbursement
  • AAA
    • AAA
    • ALTO
    • AFX2
    • EVAR for Women
    • EVAR Portfolio Resources
  • Procedural Training
  • For Patients
  • About Us
    • About Us
    • News
    • The Team
    • Careers
    • Contact Us
  • Clinical Evidence
  • PAD
    • PAD
    • DETOUR System
    • DETOUR System Evidence
    • DETOUR System Resources
    • DETOUR System Reimbursement
  • AAA
    • AAA
    • ALTO
    • AFX2
    • EVAR for Women
    • EVAR Portfolio Resources
  • Procedural Training
  • For Patients
  • About Us
    • About Us
    • News
    • The Team
    • Careers
    • Contact Us
Back to News
  • November 17, 2016

Positive Two-Year Data from the Nellix® EVAS FORWARD Global Registry Presented at 2016 VEITH Symposium

PrevPreviousPositive Five-Year Results from the Global Ovation® Pivotal Trial Presented at 2016 VEITH Symposium
NextEndologix Receives Australian Therapeutic Goods Administration (TGA) Approval for AFX®2 Bifurcated Endograft SystemNext
FIND IFU HERE
Youtube Linkedin Twitter

Compliance

Privacy Policy

Safety Information

Anti-Trafficking/Modern Slavery

Cookie Policy

Terms & Conditions

Patents

© 2025 Endologix LLC. All rights reserved.

Endologix® products and associated components are not available in all countries or regions. Please contact your Endologix representative for details regarding product availability. Prior to use, refer to the “Instructions for Use” for complete and specificindications, contraindications, all warnings and precautions. Rx only.